128 related articles for article (PubMed ID: 31681580)
1. Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.
Li X; Eguchi T; Aly RG; Chintala NK; Tan KS; Zauderer MG; Dembitzer FR; Beasley MB; Ghebrehiwet B; Adusumilli PS; Peerschke EIB
Front Oncol; 2019; 9():1042. PubMed ID: 31681580
[No Abstract] [Full Text] [Related]
2. Complement protein C1q stimulates hyaluronic acid degradation
Balduit A; Vidergar R; Zacchi P; Mangogna A; Agostinis C; Grandolfo M; Bottin C; Salton F; Confalonieri P; Rocca A; Zanconati F; Confalonieri M; Kishore U; Ghebrehiwet B; Bulla R
Front Immunol; 2023; 14():1151194. PubMed ID: 37334363
[TBL] [Abstract][Full Text] [Related]
3. gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.
Peerschke E; Stier K; Li X; Kandov E; de Stanchina E; Chang Q; Xiong Y; Manova-Todorova K; Fan N; Barlas A; Ghebrehiwet B; Adusumilli PS
Front Oncol; 2020; 10():1413. PubMed ID: 32903438
[TBL] [Abstract][Full Text] [Related]
4. Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.
Hashimoto M; Takeuchi J; Takuwa T; Kuroda A; Nakamura A; Nakamichi T; Matsumoto S; Kondo N; Nakano T; Morimoto T; Hasegawa S
J Thorac Cardiovasc Surg; 2019 Jan; 157(1):404-413. PubMed ID: 30557956
[TBL] [Abstract][Full Text] [Related]
5. Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma.
Xu J; Sun Y; Jiang J; Xu Z; Li J; Xu T; Liu P
Front Immunol; 2020; 11():1292. PubMed ID: 32760394
[TBL] [Abstract][Full Text] [Related]
6. Multi-functional, multicompartmental hyaluronan-binding protein 1 (HABP1/p32/gC1qR): implication in cancer progression and metastasis.
Saha P; Datta K
Oncotarget; 2018 Feb; 9(12):10784-10807. PubMed ID: 29535843
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
[TBL] [Abstract][Full Text] [Related]
8. BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma.
Murrone A; Cantini L; Pecci F; Cognigni V; Copparoni C; Rinaldi S; Fiordoliva I; Monaco F; Rubini C; Barbisan F; Cimadamore A; Giampieri R; Bianchi F; Tomasetti M; Amati M; Santarelli L; Berardi R
J Thorac Dis; 2021 Oct; 13(10):5741-5751. PubMed ID: 34795923
[TBL] [Abstract][Full Text] [Related]
9. An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer.
Egusquiza-Alvarez CA; Robles-Flores M
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1831-1854. PubMed ID: 35441886
[TBL] [Abstract][Full Text] [Related]
10. Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.
Klikovits T; Hoda MA; Dong Y; Arns M; Baumgartner B; Errhalt P; Geltner C; Machan B; Pohl W; Hutter J; Eckmayr J; Studnicka M; Flicker M; Cerkl P; Kirchbacher K; Klepetko W
Wien Klin Wochenschr; 2016 Sep; 128(17-18):627-34. PubMed ID: 27457873
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS
Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326
[TBL] [Abstract][Full Text] [Related]
12. gC1qR: A New Target for Cancer Immunotherapy.
Lei Y; Li X; Qin D; Zhang Y; Wang Y
Front Immunol; 2023; 14():1095943. PubMed ID: 36776869
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma in Singapore.
Yip CS; Koong HN; Loo CM; Fong KW
Asian Pac J Cancer Prev; 2011; 12(5):1155-9. PubMed ID: 21875258
[TBL] [Abstract][Full Text] [Related]
14. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
[TBL] [Abstract][Full Text] [Related]
15. Significance of hyaluronan binding protein (HABP1/P32/gC1qR) expression in advanced serous ovarian cancer patients.
Yu G; Wang J
Exp Mol Pathol; 2013 Feb; 94(1):210-5. PubMed ID: 22771308
[TBL] [Abstract][Full Text] [Related]
16. CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma.
Liu L; Hui R; Zeng T; Yang X; Wu Q; Yang T
Int J Gen Med; 2022; 15():4613-4623. PubMed ID: 35535145
[TBL] [Abstract][Full Text] [Related]
17. The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)
Ghebrehiwet B; Geisbrecht BV; Xu X; Savitt AG; Peerschke EIB
Semin Immunol; 2019 Oct; 45():101338. PubMed ID: 31744753
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
19. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Kao SC; Lee K; Klebe S; Henderson D; McCaughan B; Vardy J; Clarke S; van Zandwijk N
Clin Lung Cancer; 2013 Mar; 14(2):164-71. PubMed ID: 23085037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
